Icon
+91 94997 68112
Login Register

NESINA - (6.25,12.5,25 mg; Tablet, Oral)

ALOGLIPTIN BENZOATE Takeda
6.25,12.5,25 mg; Tablet, Oral
Less Than $1000 mn
Less Than 5
More Than 5
Less Than 5
More Than 5
None None
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Yes
******* ** **** ** ****** ** ****** *** ****** **** **** ******** ******®, ******®, *** *****® **** *** ********** ******* *** ********** ******** ** *********** ** ********* ************* *** ************ ************* ************. *** ****** ******* *** ********* **** ** ************* *** ******* (*** **, ****), ******* (*** *, ****), ******* (*** **, ****)- ** ******* *** *********. *** ** ****** **** ****** ** ***. ****. ** ** ********* ** **** **** *** *** ****** ****** ** ***** **** ********* ***-* ********* ******** ***** *********** *** ********** ****** ****** *** ******* ******** ** ********* ***** ** ***** *******. ******** ******, *******, *** **** *** ****** ***** * **** ** ***, **** **** *** *********. **** ***** * **** *** ** ****** '*** (**** **, ****). *********, **** ***'* ****** ******* ****** **** ****. *****, ***** ***** ** ***** ** ********* *** ******* ******* *** ****** ******** **** **** ********* ****** ******* (**** **, ****). *********, *** **** ** ******** *** *** ** ******* **** *** **** ** *** ********** ** *.*. ****** **. ******* (*.* ***** **** ****)
NESINA Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8
******* **** *** **** *** **** *** **** ** ** *** ** ******* ******* ******* *******
****** ******** ******* ******* ******* **** ** ** *** ** ******* ******* ******* *******
******** ****** *** ********* *** ********* *** ********* **** *** **** *** **** *** *** ********* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ ** *** *, **** ********* **** ** ** *** ** ********* ******** ** **** **, ****
****** ******** ** \ ** ***** **, **** ********* **** ** ** *** ** ********* ******** ** **** **, ****
******** ****** ** \ ** *** ********* *** ********* ********* ******** ** **** **, ****
  1. *** *, **** : ******* ******** ****** ********* *** **** ** ******* ******* (*** **, ****), ******* (*** *, ****), ******* (*** **, ****)- ** *******
  2. *** *, **** : ****** **** ******* ** ** ** **.
  3. *** **, **** : ****** ******** ****** ********* **'* **** ** ******* ******* (*** **, ****), ******* (*** *, ****), ******* (*** **, ****)
  4. *** **, **** : ****** **** ****** ** ** ** **.
  5. *** *, **** : ***** ***** ** ***** ** ********* *** ******* ******* *** ****** ******** **** ****** '*** *** ***** *** **** ********* ****** ******* (**** **, ****).
  6. *** **, **** : *** ** **** ***** ********* ** *** ***** **** ******* *** ****** *** ****** ******* ***** ********** ** ****** ******* (**** **, ****)
  7. *** *, **** : ******* ******** ** **
  8. *** **, **** : ****** ******** ** **
  9. *** **, **** : ******* *** ****** **** ** **.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.